61
Participants
Start Date
August 14, 2023
Primary Completion Date
December 13, 2024
Study Completion Date
December 13, 2024
MAM01 1.5 mg/kg
1.5 mg/kg MAM01 will be administered via IV route.
Placebo
Placebo will be administered via IV route.
MAM01 5 mg/kg
5 mg/kg MAM01 will be administered via SC route.
MAM01 10 mg/kg
10 mg/kg MAM01 will be administered via IV route.
MAM01 40 mg/kg
40 mg/kg MAM01 will be administered via IV route.
MAM01 450 mg
MAM01 will be administered via SC route.
Placebo
Placebo will be administered via SC route.
MAM01 5 mg/kg
5 mg/kg MAM01 will be administered via IV route.
Control
No drug or placebo will be administered.
MAM01 600 mg
MAM01 will be administered via SC route.
MAM01 900 mg
MAM01 will be administered via SC route.
Center for Vaccine Development and Global Health, 685 W. Baltimore Street, Baltimore
Lead Sponsor
Gates Medical Research Institute
OTHER